- Home
- MQ vs BCYC Comparison
MQ vs BCYC Comparison
Compare MQ & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQ
- BCYC
- Stock Information
- Founded
- MQ 2010
- BCYC 2009
- Country
- MQ United States
- BCYC United Kingdom
- Employees
- MQ N/A
- BCYC N/A
- Industry
- MQ Computer Software: Prepackaged Software
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- MQ Technology
- BCYC Health Care
- Exchange
- MQ Nasdaq
- BCYC Nasdaq
- Market Cap
- MQ 1.9B
- BCYC 1.7B
- IPO Year
- MQ 2021
- BCYC 2019
- Fundamental
- Price
- MQ $3.73
- BCYC $14.87
- Analyst Decision
- MQ Buy
- BCYC Buy
- Analyst Count
- MQ 16
- BCYC 9
- Target Price
- MQ $5.77
- BCYC $35.25
- AVG Volume (30 Days)
- MQ 5.6M
- BCYC 883.8K
- Earning Date
- MQ 11-04-2024
- BCYC 02-18-2025
- Dividend Yield
- MQ N/A
- BCYC N/A
- EPS Growth
- MQ N/A
- BCYC N/A
- EPS
- MQ 0.03
- BCYC N/A
- Revenue
- MQ $490,027,000.00
- BCYC $36,898,000.00
- Revenue This Year
- MQ N/A
- BCYC $39.81
- Revenue Next Year
- MQ $15.52
- BCYC N/A
- P/E Ratio
- MQ $137.79
- BCYC N/A
- Revenue Growth
- MQ N/A
- BCYC 48.60
- 52 Week Low
- MQ $3.37
- BCYC $12.17
- 52 Week High
- MQ $7.36
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- MQ 37.31
- BCYC 29.27
- Support Level
- MQ $3.61
- BCYC $12.17
- Resistance Level
- MQ $3.86
- BCYC $17.04
- Average True Range (ATR)
- MQ 0.15
- BCYC 1.37
- MACD
- MQ 0.00
- BCYC -0.22
- Stochastic Oscillator
- MQ 12.26
- BCYC 27.65
About MQ Marqeta Inc.
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.